Published in FDA Law Weekly, March 12th, 2009
The FDA has said it has no evidence the drugs on the market are substandard and also that they comply with specifications upon testing.
No products from Ranbaxy's other manufacturing facilities are included in the AIP.
Ranbaxy will continue to co-operate with the USFDA. Further, no effort or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.